로딩 중...
52주 최고가 대비 88.9% 위치
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $101.17B | $59.55B | $63.63B | $62.58B |
| 영업이익 | - | $37.16B | $4.22B | $14.83B | $15.79B |
| 당기순이익 | - | $31.37B | $2.12B | $8.03B | $7.77B |
| 잉여현금흐름 (FCF) | - | $26.03B | $4.79B | $9.84B | $9.07B |
| 수익성 비율 | |||||
| 영업이익률 | - | 36.7% | 7.1% | 23.3% | 25.2% |
| 순이익률 | - | 31.0% | 3.6% | 12.6% | 12.4% |
| ROE (자기자본이익률) | - | 32.8% | 2.4% | 9.1% | 9.0% |
| ROA (자산이익률) | - | 15.9% | 0.9% | 3.8% | 3.7% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | -41.1% | 6.8% | -1.6% |
| EPS 성장률 (YoY) | - | - | -93.2% | 281.1% | -3.5% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | 6.6x | 62.2x | 17.0x | 18.8x |
| PBR (주가순자산배수) | - | 2.1x | 1.5x | 1.5x | 1.7x |
| PSR (주가매출배수) | - | 2.0x | 2.2x | 2.1x | 2.3x |
| FCF Yield | - | 12.7% | 3.7% | 7.2% | 6.2% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.36 | 0.80 | 0.72 | 0.74 |
| 유동비율 | - | 1.22 | 0.91 | 1.17 | 1.16 |
MOLINA HEALTHCARE INC
$179.86
$9.4B